INTRODUCTION
The clinical outcome of patients with metastatic colorectal cancer (CRC) has improved, with an increase in median overall survival from 8-12 months in the 1990s to currently more than 20 months, along with a not negligible proportion of patients still alive at 5 and 10 years. This improvement in treatment efficacy has been achieved mainly following the clinical use of highly active cytotoxic agents (e.g., irinotecan, oxaliplatin) and, more recently, of molecular targeted therapies (e.g.,cetuximab, panitumumab, and bevacizumab) (1) and through the multidisciplinary management of patients. Resection of liver metastases upfront or after neoadjuvant chemotherapy has been consistently demonstrated to prolong survival (2) .
At the time of advanced disease presentation, pulmonary CRC metastases are revealed in approximately 10-15% of the patients (3) . The best estimate of isolated lung metastases (i.e. without localization in other organs) lie between 1.7% and 7.4% (4) . The management of this latter subgroup of patients is a matter of debate. Surgical resection is a widespread clinical practice.
Several studies describing single institution series of resected patients reported 5-year survival rates between 21% and 61.4%, exceeding those normally associated with metastatic colorectal cancer (5) (6) (7) . This notable difference in 5-year survival rates within surgical studies reflects the quality of evidence for pulmonary metastasectomy that is insufficient to draw definitive conclusions (8) . In fact, while some Authors demonstrated stage of the primary tumor, distribution of the metastases, disease free interval, CEA, gender, age, complete resection (R0), number of lung metastases, and vascular and lymphatic invasion to be variables influencing 5-year survival rate, others reported opposite findings (9) . Moreover, inclusion criteria guidelines for lung metastasectomy published by several institutions lie on the experience of the single institution (10) (11) (12) . Despite these discrepancies, the reported outcomes are widely held to corroborate the benefit gained from lung surgery when compared to historical series. To solve the debate, a phase III prospective randomized clinical trial designed to compare patients with lung metastases to be allocated to "active monitoring" or "active monitoring with pulmonary metastasectomy" has been advocated (13) .
To our knowledge, there is no study which compared the outcome in CRC patients with lung metastases, surgically resected or not, followed and treated at the same institutions and in the same timeframe. In this retrospective study we searched the databases of three institutions and extracted the data on patients consecutively followed and treated from the time of first appearance of metastatic disease. We then compared their outcomes according to whether they were submitted or not to lung metastasectomy. Three subgroups of patients were identified : group 1 (G1) including patients with at least one organ involved other than the lung; group 2 (G2) including patients with lung metastases as the sole site of advanced disease and not submitted to lung surgery; group 3 (G3) patients with lung metastases as the sole site of advanced disease and submitted to lung surgery ( Figure 1 ).
PATIENTS AND METHODS

Patients
Outcome evaluation
Response evaluation was performed under the standard assessment criteria used at each institution for the considered timeframe. Progression-free survival and overall survival were estimated from first-line treatment onset till progression or death from any cause or date of the last follow-up. The cut-off date for the collection of data was January 31 st , 2011. Patients not progressing or alive or lost to follow-up at the time of the cut-off date were censored at the time of the last follow-up examination.
Surgical criteria
All patients with lung metastases were considered for lung resection at two thoracic surgery centers, one located at University of Torino, San Luigi Gonzaga Hospital (also referral center for the Oncology Unit at IRCC Candiolo) and the second one at University of Eastern Piedmont, Maggiore della Carità Hospital, Novara. While each institution evaluated patient eligibility for lung resection according to its own internal diagnostic work up procedures and by a multidisciplinary team which included the thoracic surgeon, the mandatory criteria requested for the inclusion in this retrospective study were: resection with curative intent and with a predicted adequate residual pulmonary reserve after surgery in the absence of unresectable non-pulmonary localization. Surgery was performed upfront when resectability criteria were met. A surgical re-evaluation was planned in case of tumor response or stabilization after chemotherapy.
Statistical analyses
Differences between proportions were evaluated using the chi-square test with Yates correction, when necessary. Differences between groups of non parametric unpaired variables were validated by the Mann-Whitney U test when comparing two groups or the Kruskal-Wallis Analysis of
Variance when analyzing multiple groups. Logistic regression analysis was performed to eliminate confounding parameters when examining dichotomous variables. Survival curves were plotted using the Kaplan-Meier method and validated using the log-rank test. Multivariate survival analysis was performed according to the Cox proportional-hazards model. All statistical computations were performed using SPSS for Windows Ver 16.0 and STATISTICA for Windows Ver. 6.0 software.
RESULTS
Patient characteristics
Data from 1411 CRC patients (Table 1) were retrospectively considered, 409 of which presented with lung metastases and composed the primary dataset for the present analyses. Patients were grouped as follows: G1 composed of patients with lung and extra-pulmonary metastases (n= 255);
G2 composed of patients with the lung as the sole metastatic site and not submitted to lung resection (n=104); G3 included patients submitted to resection (n=50) ( Figure 1 ). Surgery was performed after neoadjuvant chemotherapy in 19 out of 50 patients. Table 2 summarizes the characteristics of the 409 patients included in the study.
The three groups were comparable for gender, Eastern Cooperative Oncology Group (ECOG) performance status, and circulating serum prognostic factors such as lactate dehydrogenase (LDH), carcinoembrionic antigen (CEA) and alkaline phosphatase (ALP). There was an expectedly higher proportion of colon cancers in group 1 than in the other two groups but no difference was observed between G2 and G3. Patient age and tumor stage at diagnosis were fairly similar in G1 and G2. The median age was significantly lower in G3 than in group 2 (60.8 and 65.9 years, respectively; p <0.004) and there was a higher proportion of metachronous tumors in G3 than in G2 (88% and 56.7%, respectively; X 2 p <0.0001). Median disease free interval was higher in G3 than in G2 and G1 (23.7, 5, and 0.5 months, respectively. ANOVA p<0.001).
Chemotherapy and lung surgery
A total of 371/409 (98.1%) patients received chemotherapy as first-line treatment; 7/409 were not treated because of poor performance status (n=2), concomitant invalidating diseases (n=2), and unknown reasons (n=3). Thirty-one patients in G3 received lung surgery upfront and were not subsequently evaluable for chemotherapy response. The choice about systemic chemotherapy was left to each investigator center discretion. The majority of patients (262/371, 70.6%) received an oxaliplatin-containing doublet, 51/371 (13.8%) received an irinotecan-based chemotherapy, and 56 (15.1%) a fluoropyrimidine-based chemotherapy. Two patients received a triplet. Nineteen patients in G2 (18.5%) received a single agent fluoropyrimidine chemotherapy as they were considered unfit (older patients or those with other comorbidities), and one patient in G3 received a triplet. No more difference in the type of chemotherapy administered between G2 and G3 was found ( Resection was complete (R0) in 49/50 patients. In only one patient residual tumor was microscopically documented in the surgical margins. One other patient underwent a second complete lung resection 1 month after the first surgical treatment.
Twenty-one patients in G2 who present resectable disease, surgery was not performed due to lung disease or other health conditions (mainly poor lung function reserve or cardiac disease). Eight patients in G1 with liver and lung metastases were submitted to liver and then to lung resection.
The proportion of patients submitted to lung resection was higher in those centers with in house thoracic surgery facilities: 21/53 (39.6%) in center 1; 15/32 (46.9%) in center 3; 14/69 (20.3%) in center 2 (center 1 vs. center 2, X 2 p=0.01). However, there was no difference between centers in the proportion of patients with 6 or less lung metastases (the upper range of G3) not submitted to surgery (i.e. patients in G2), nor in their distribution (ANOVA p>0.5 for both analyses).
Clinical outcomes
At the time of data computation (January 31 st 2011), 334/409 (81.7%) patients had progressed. The median progression-free survival of the entire population was 11.3 months. At the cut-off date of data collection, 14/50 resected patients (G3) (28%) had died. The remaining 36 patients still alive were followed for a median of 41.3 months (range, 4.0-134.1). Seventeen (34%) were alive for more than 5 years (five of them without sign of disease) and 3 (6%) for more than 10 years (two disease-free) after diagnosis of advanced CRC, whereas only 4 (4.8%) of those patients in group 2 (patients with lung metastases not submitted to resection) were alive after 5 years (all with progressive disease). Rectal localization, disease-free interval (as a continuous variable), hemoglobin level >12 g/dl, ECOG performance status, and surgery of liver and lung metastases were found to be independent factors for progression-free survival (Table 3) . Age, treatment center, tumor stage at diagnosis, grading, gender, and number of metastatic sites did not enter the model.
Multivariate analyses
Disease-free interval (as a continuous variable), the presence of liver metastases, hemoglobin level
>12 g/dl, number of metastatic sites, and surgery of liver and lung metastases were found to be independent factors of overall survival (Table 4) . Age, treatment center, tumor stage at diagnosis, grading, gender, ECOG performance status, and rectal localization did not enter the model.
DISCUSSION
In this large retrospective study in metastatic CRC patients we observed a remarkably longer duration of progression-free survival and overall survival in patients submitted to resection with radical intent of their pulmonary metastases compared to those who received chemotherapy alone. This is the first study to compare outcomes in the same series of patients and not against historical reports.
The incidence of synchronous lung metastases was higher in our study population than that previously reported (16): 29% of patients presented synchronous lung metastases and 10.9% had only lung localizations. This may be explained in part by the fact that the staging procedure included thoracic computed tomography (CT), which has been demonstrated to be more sensitive than conventional X-ray (17) . Nearly one third of the patients (50/154) with the lung as the sole metastatic site underwent surgery. This number does not include the 8 patients submitted to liver and subsequently to pulmonary resection, as they were included in G1 (patients with lung and extra-pulmonary metastases) in an intention to treat analysis.
Not surprisingly, patients submitted to surgery were, on average, younger. The incidence of chronic lung diseases such as chronic obstructive pulmonary disease increases with age. As a consequence of these chronic comorbilities, older subjects more frequently have poor lung function reserve and are ineligible for surgery, as it was the case for 21 patients in this study. This might represent a selection bias, as younger patients are assumed to have a longer duration of survival, even if other series have not shown this difference (18), or even reported an opposite pattern (19) . As demonstrated by the logistic regression analysis, age, disease free interval and the number of metastases are the variables that drove surgeons through the decision process. Even though discrepant results have been reported in literature on the possible prognostic role of these three variables, it is reasonable to think that resected patients were those destined to have per se a longer survival as they were younger, presented with a longer disease free interval and a lower number of lung metastases than those not submitted to surgery.
One open question concerns whether the strikingly longer survival of patients submitted to lung resection is due to the beneficial effect of surgery itself or to the selection bias above described (21, 22) . There is a large body of literature reporting survival benefits gained from lung resection (5) (6) (7) (18) (19) (20) (21) (22) . However, a sort of citation cascade of the same few studies reporting these survival benefits excluding those with negative results might have resulted in an unfounded "authority of claim" as recently demonstrated by Fiorentino et al. (8) . Optimally this question could be definitively answered by a phase III trial (13) . However, if it could be indirectly demonstrated that surgery is effectively beneficial in curing patients or at least prolonging survival, such a comparative trial would have lower priority from a medical oncology point of view; such was the case for surgery for the treatment of liver metastasis.
Our data confirm a better outcome in those patients submitted to surgery than in those treated with chemotherapy alone in the same institutions and during the same period of time. In the resected subgroup, 17 patients are alive after more than 5 years and 3 more than 10 years after the diagnosis of advanced cancer, whereas only 4 of those in G2 are alive after 5 years. Interestingly, of the 8 patients in G1 submitted to liver and subsequently lung resection, the duration of survival was 5 years in 2 patients and 10 years in 1 patient.
Several published studies have discussed the importance of finding surrogate end points as outcome indicators. Response rate and progression-free survival after first-line treatment have been proposed and validated in CRC patients (23) (24) (25) as their evaluation allows a reliable quantitative estimate of the efficacy of new drugs or new techniques with a lower degree of potential bias. In our retrospective study, patients were treated with chemotherapy (G1 and 2) or with surgery. Response to first-line treatment was similar in G1 and G2 (36.1 and 35.9%, respectively). Determining treatment response in G3 patients was difficult because 31 patients received surgery before chemotherapy: if we take into account only the 19 patients who received chemotherapy before surgery, the response rate was 73.7%; if we consider, however, surgery as an active first-line treatment, the response rate of the whole group was 98%, as residual tumor after surgery (R1) was evident in only 1 patient. Patients submitted to surgery presented a median duration of progressionfree survival of 26.2 months, more than twice that recorded in those not resected (10.5 months).
Interestingly, the duration of progression-free survival was similar for G1 and G2 (10.3 months). At multivariate analyses of the complete patient dataset of 1411 subjects, liver and lung surgery emerged as independent factors for both progression-free and overall survival. These findings further suggest that surgery is a more active treatment than chemotherapy alone.
In conclusion, the results of our retrospective study provide evidence suggesting that surgery is a more active treatment than chemotherapy alone when performed as first-line treatment. Although resectable patients are probably those destined to have a more indolent form of the disease as they have theoretically favorable prognostic factors, surgery can further improve their outcome. In our study we recorded 10-year survivors only in G3 and G1 (1 patient submitted to liver and then lung resection), but not in G2 in which some potentially resectable patients might have been included.
Moreover, resected patients had a longer duration of progression-free survival, a validate surrogate end-point for clinical outcome. From a statistical point of view, our findings are insufficient to definitively solve the question of whether surgery is beneficial in resectable patients as this can be demonstrated only with a prospective randomized phase III trial. From a medical oncology point of view, however, our results add evidence to the debate whether such a study is still necessary. 
